Keeping Track: After COVID Delays, US FDA Approvals At Last For Daxxify, Rolvedon (But A CRL For Alvotech)
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
The Quality Lowdown: Alvotech, Lupin, Cipla, Lilly, Rentschler Inspection Findings And Akorn Recall
US FDA finds flawed data integrity, investigations, aseptic practices and more at range of foreign and domestic drug product manufacturing facilities, while a bankruptcy leads to a massive drug recall.
Assertio Targets Febrile Neutropenia Drug In Spectrum Buyout Deal
It remains unclear whether Rolvedon will achieve hoped-for sales milestones in a deal that Assertio said was part of a growth strategy emphasizing product and business acquisitions.
Merck Reports Good News/Bad News In Latest Keytruda Readouts
With successful Phase III data, Merck will look to add biliary tract cancer to Keytruda’s label, but it will discontinue a Phase III study in prostate cancer after an interim analysis showed no survival benefit.